Biomea Fusion Company

Biomea Fusion is a privately held precision medicine company with a mission to revolutionize drug development to create more effective therapies for cancer patients. Biomea Fusion has a development portfolio that targets specific gene alterations which occur in the DNA of patients that translate into key drivers of tumor growth. It is Biomea’s goal to move these potentially breakthrough medicines swiftly through the development process and deliver highly impactful treatments for patients in need. The lead program targets the protein-to-protein interaction between menin and the MLL complex for the treatment of various tumors.
Technology: Biotechnology, Life Science, Therapeutics
Industry: Early Drug Development
Headquarters: Redwood City, California, United States
Founded Date: 2017-01-01
Employees Number: 11-50
Funding Status: IPO
Investors Number: 8
Total Funding: 56000000
Last Funding Date: 2021-01-06
Last Funding Type: Series A

Visit Website
Register and Claim Ownership